If you are using a GLP-1 medication, it may be helpful to work with a healthcare provider to better understand your nutritional needs and determine what type of support is right for you.
Frequently Asked Questions Retatrutide is not yet FDA approved
At the end of 40 or 42 weeks (study time varied by trial), urine albumin-to-creatinine ratio (UACR) was significantly reduced among participants assigned to tirzepatide 5, 10, or 15 mg as compared with those assigned to all pooled comparators (placebo, semaglutide, insulin degludec, and insulin glargine) with adjusted mean percent changes of 19.3% [95% CI 12.525.5%], 22.0% [95% CI 15.328.1%], and 26.3% [95% CI 20.032.0%], respectively, with a greater reduction observed in participants with a UACR 30 mg/g at baseline [96]
NAD+ is ideal for patients focused on anti-aging, cognitive clarity, addiction recovery, chronic fatigue, or neurological optimization
Immediate medical attention is required if thirst is accompanied by any of the following: Severe or persistent vomiting or diarrhoea leading to inability to maintain hydration Signs of dehydration such as dizziness, reduced urine output, dark-coloured urine, or dry mucous membranes Symptoms suggestive of hypoglycaemia (blood glucose below 4 mmol/L) that do not resolve with standard treatment Severe abdominal pain, which may indicate pancreatitisa rare but serious adverse effect of GLP-1 receptor agonists Symptoms of DKA, including rapid breathing, fruity breath odour, confusion, or loss of consciousness If pancreatitis is suspected (severe, persistent abdominal pain, possibly radiating to the back), stop taking semaglutide and seek urgent medical assessment
GLP-1 agonists include semaglutide, liraglutide, dulaglutide, and tirzepatide, used for type 2 diabetes and weight management